✦ LIBER ✦

Determination of the Critical Amino Acids Involved in the Peroxisome Proliferator-Activated Receptor (PPAR) δ Selectivity of Phenylpropanoic Acid-Derived Agonists

✍ Scribed by Jun-ichi Kasuga; Takuji Oyama; Izumi Nakagome; Makoto Makishima; Shuichi Hirono; Kosuke Morikawa; Yuichi Hashimoto; Hiroyuki Miyachi

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 761 KB
Volume: 3
Category: Article
ISSN: 1860-7179
DOI: 10.1002/cmdc.200800193

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and Synthesis of Substituted Phen

Design and Synthesis of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator-Activated Receptor α/δ Dual Agonists.

✍ Jun-ichi Kasuga; Makoto Makishima; Yuichi Hashimoto; Hiroyuki Miyachi 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 12 KB 👁 1 views

ChemInform Abstract: Design, Synthesis a

ChemInform Abstract: Design, Synthesis and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Peroxisome Proliferator-Activated Receptor (PPAR) Activators: Novel Human PPARα-Selective Activators.

✍ Hiroyuki Miyachi; Masahiro Nomura; Takahiro Tanase; Yukie Takahashi; Tomohiro Id 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 2 views

ChemInform Abstract: α-Alkyl Substituted

ChemInform Abstract: α-Alkyl Substituted Pirinixic Acid Derivatives as Potent Dual Agonists of the Peroxisome Proliferator Activated Receptor α and γ.

✍ Oliver Rau; Yvonne Syha; Heiko Zettl; Michael Kock; Andreas Bock; Manfred Schube 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 24 KB 👁 1 views

The synthesis of three isotopomers of 2-

The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist

✍ Fengjiun Kuo; Dean K. Clodfelter; Nagy A. Farid; William J. Wheeler; Lennon H. M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 184 KB

## Abstract Although fenofibrate (**1a**) is commercially available and clinically effective in lowering serum triglycerides, its activity and sub‐type selectivity at the PPARα receptors are only moderate; therefore, there exists a need for more potent and sub‐type selective PPARα agonists. To that